Bank Julius Baer & Co. Ltd Zurich Invests $211,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Bank Julius Baer & Co. Ltd Zurich bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 4,861 shares of the company’s stock, valued at approximately $211,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. ARK Investment Management LLC lifted its position in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock valued at $353,180,000 after buying an additional 1,474,439 shares during the last quarter. Baker BROS. Advisors LP lifted its holdings in CRISPR Therapeutics by 743.1% during the 3rd quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares during the last quarter. State Street Corp boosted its position in CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock worth $140,611,000 after purchasing an additional 599,304 shares during the period. Raymond James Financial Inc. acquired a new position in shares of CRISPR Therapeutics in the fourth quarter valued at $3,231,000. Finally, Van ECK Associates Corp lifted its stake in shares of CRISPR Therapeutics by 5,269.3% during the 4th quarter. Van ECK Associates Corp now owns 83,010 shares of the company’s stock worth $3,267,000 after buying an additional 81,464 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on CRSP shares. Barclays increased their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a report on Wednesday, February 12th. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and increased their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Citigroup reduced their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Bank of America lowered their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Morgan Stanley boosted their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday, February 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Stock Down 4.8 %

CRISPR Therapeutics stock opened at $43.34 on Tuesday. The stock has a market cap of $3.72 billion, a PE ratio of -9.92 and a beta of 1.77. CRISPR Therapeutics AG has a 12-month low of $36.52 and a 12-month high of $79.33. The business’s 50-day moving average price is $42.88 and its two-hundred day moving average price is $45.71.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. As a group, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director John Greene bought 7,000 shares of the stock in a transaction that occurred on Wednesday, February 26th. The shares were bought at an average cost of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now owns 7,000 shares in the company, valued at $313,950. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.10% of the stock is currently owned by corporate insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.